Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.098
Neutral
RSI(14)
41.877
Neutral
STOCH(KDJ)(9,3,3)
31.279
Neutral
ATR(14)
0.176
Low Volatility
CCI(14)
-125.637
Sell
Williams %R
70.769
Sell
TRIX(12,20)
-0.086
Sell
StochRSI(14)
26.695
Buy
Aytu Biopharma Inc
AYTU2.390USD
+0.090+3.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
23.69MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Aytu Biopharma Inc
Currency: USD Updated: 2026-02-06Key Insights
Aytu Biopharma Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 88 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.33.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aytu Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aytu Biopharma Inc Highlights
StrengthsRisks
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Growing
The company is in a growing phase, with the latest annual income totaling USD 66.38M.
Fairly Valued
The company’s latest PE is -1.09, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 95.12K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.49.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.333
Target Price
+305.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Aytu Biopharma Inc is 7.49, ranking 111 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.89M, representing a year-over-year decrease of 16.21%, while its net profit experienced a year-over-year decrease of 33.31%.
Score
Financials
6.11
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.39
Operational Efficiency
10.00
Growth Potential
7.70
Shareholder Returns
7.27
Aytu Biopharma Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Aytu Biopharma Inc is 7.38, ranking 75 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -1.09, which is -1290.07% below the recent high of 12.96 and -96.26% above the recent low of -2.14.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 88/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Aytu Biopharma Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 8.00, with a high of 12.50 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.333
Target Price
+305.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Aytu Biopharma Inc
AYTU
3
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Aytu Biopharma Inc is 6.81, ranking 104 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.77 and the support level at 2.10, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.474
Sell
MA10
2.549
Sell
MA20
2.615
Sell
MA50
2.497
Sell
MA100
2.335
Buy
MA200
2.191
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Aytu Biopharma Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 34.64%, representing a quarter-over-quarter decrease of 2.72%. The largest institutional shareholder is The Vanguard, holding a total of 278.58K shares, representing 2.60% of shares outstanding, with 474.23% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Nantahala Capital Management, LLC
Stonepine Capital Management, LLC
AWM Investment Company, Inc.
Diadema Partners LP
Disbrow (Joshua R.)
Lytton (Laurence W)
Two Sigma Investments, LP
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aytu Biopharma Inc is 3.32, ranking 104 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Aytu Biopharma Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.
Score
Beta vs S&P 500 index
0.37
VaR
+9.09%
240-Day Maximum Drawdown
+42.47%
240-Day Volatility
+97.63%
Return
Best Daily Return
60 days
+6.54%
120 days
+15.26%
5 years
+483.33%
Worst Daily Return
60 days
-10.31%
120 days
-17.93%
5 years
-100.00%
Sharpe Ratio
60 days
+0.81
120 days
+0.33
5 years
+0.10
Risk Assessment
Maximum Drawdown
240 days
+42.47%
3 years
+70.24%
5 years
+99.27%
Return-to-Drawdown Ratio
240 days
+1.97
3 years
+0.05
5 years
-0.20
Skewness
240 days
-9.18
3 years
-1.14
5 years
+22.26
Volatility
Realised Volatility
240 days
+97.63%
5 years
+93.97%
Standardised True Range
240 days
+5.97%
5 years
+37.09%
Downside Risk-Adjusted Return
120 days
+43.04%
240 days
+43.04%
Maximum Daily Upside Volatility
60 days
+47.38%
Maximum Daily Downside Volatility
60 days
+45.14%
Liquidity
Average Turnover Rate
60 days
+4.99%
120 days
+11.49%
5 years
--
Turnover Deviation
20 days
-48.67%
60 days
+51.39%
120 days
+248.38%
Peer Comparison
Pharmaceuticals
Aytu Biopharma Inc
AYTU
6.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
